AbbVie Inc (ABBV)vsSafeplus International Holdings Limited (BIPH)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
BIPH
Safeplus International Holdings Limited
$15.66
+0.58%
HEALTHCARE · Cap: $357,540
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9497341% more annual revenue ($64.39B vs $677,930). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
BIPH
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for BIPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
17.1% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 1565.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : BIPH
The strongest argument for BIPH centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : BIPH
The primary concerns for BIPH are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 12.99 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while BIPH is a growth play — different risk/reward profiles.
BIPH carries more volatility with a beta of 1.04 — expect wider price swings.
BIPH is growing revenue faster at 17.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 40/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Safeplus International Holdings Limited
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Biophan Technologies, Inc. develops and markets various technologies for the medical device industries. The company is headquartered in Pittsford, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?